-
1
-
-
0028004222
-
A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group
-
Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
-
(1994)
J Intern Med
, vol.236
, pp. 391-399
-
-
Aledort, L.M.1
Haschmeyer, R.H.2
Pettersson, H.3
-
2
-
-
0033028402
-
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
-
Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
-
(1999)
Br J Haematol
, vol.105
, pp. 1109-1113
-
-
Astermark, J.1
Petrini, P.2
Tengborn, L.3
Schulman, S.4
Ljung, R.5
Berntorp, E.6
-
3
-
-
0036529818
-
The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia
-
Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
-
(2002)
Blood
, vol.99
, pp. 2337-2341
-
-
Fischer, K.1
van der Bom, J.G.2
Mauser-Bunschoten, E.P.3
-
4
-
-
34547757915
-
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
-
Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
-
(2007)
N Engl J Med
, vol.357
, pp. 535-544
-
-
Manco-Johnson, M.J.1
Abshire, T.C.2
Shapiro, A.D.3
-
5
-
-
0033909528
-
Articular cartilage is more susceptible to blood induced damage at young than at old age
-
Roosendaal G, Tekoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatology 2000; 27: 1740-4.
-
(2000)
J Rheumatology
, vol.27
, pp. 1740-1744
-
-
Roosendaal, G.1
Tekoppele, J.M.2
Vianen, M.E.3
van den Berg, H.M.4
Lafeber, F.P.5
Bijlsma, J.W.6
-
6
-
-
0026635406
-
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
-
Nilsson IM, Berntorp E, Lofquist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
-
(1992)
J Intern Med
, vol.232
, pp. 25-32
-
-
Nilsson, I.M.1
Berntorp, E.2
Lofquist, T.3
Pettersson, H.4
-
7
-
-
77951681450
-
A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A
-
Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
-
(2010)
Br J Haematol
, vol.149
, pp. 498-507
-
-
Richards, M.1
Williams, M.2
Chalmers, E.3
-
8
-
-
0013836217
-
Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B
-
Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; Suppl. 77: 3-132.
-
(1965)
Acta Orthop Scand Suppl
, Issue.SUPPL. 77
, pp. 3-132
-
-
Ahlberg, A.1
-
9
-
-
0027324261
-
Experience with prophylaxis in Sweden
-
Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993; 30: 16-9.
-
(1993)
Semin Hematol
, vol.30
, pp. 16-19
-
-
Nilsson, I.M.1
-
10
-
-
0036827020
-
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
-
Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
-
(2002)
Haemophilia
, vol.8
, pp. 753-760
-
-
Fischer, K.1
Astermark, J.2
van der Bom, J.G.3
-
11
-
-
59849093369
-
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
-
Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 413-420
-
-
Collins, P.W.1
Blanchette, V.S.2
Fischer, K.3
-
12
-
-
34548180049
-
Measurement of global haemostasis in severe haemophilia A following factor VIII infusion
-
Lewis SJ, Stephens E, Florou G et al. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. Br J Haematol 2007; 138: 775-82.
-
(2007)
Br J Haematol
, vol.138
, pp. 775-782
-
-
Lewis, S.J.1
Stephens, E.2
Florou, G.3
-
13
-
-
84857951468
-
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
-
Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-53.
-
(2011)
Haemophilia
, vol.17
, pp. 849-853
-
-
Den Uijl, I.E.M.1
Mauser Bunschoten, E.P.2
Roosendaal, G.3
-
14
-
-
79951472629
-
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
-
Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
-
(2011)
Haemophilia
, vol.17
, pp. 2-10
-
-
Collins, P.W.1
Fischer, K.2
Morfini, M.3
Blanchette, V.S.4
Bjorkman, S.5
-
15
-
-
77954851703
-
Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A
-
Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
-
(2010)
Haemophilia
, vol.16
, pp. 597-605
-
-
Bjorkman, S.1
-
16
-
-
79951902782
-
Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII
-
Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia 2011; 17: e239-e340.
-
(2011)
Haemophilia
, vol.17
-
-
Bjorkman, S.1
-
17
-
-
84855853759
-
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
-
Bjorkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
-
(2012)
Blood
, vol.119
, pp. 612-618
-
-
Bjorkman, S.1
Oh, M.2
Spotts, G.3
-
18
-
-
74749088081
-
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
-
Collins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 269-275
-
-
Collins, P.W.1
Bjorkman, S.2
Fischer, K.3
-
19
-
-
77952712296
-
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
-
Bjorkman S, Blanchette VS, Fischer K et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730-6.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 730-736
-
-
Bjorkman, S.1
Blanchette, V.S.2
Fischer, K.3
-
20
-
-
73049092113
-
Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study
-
Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 83-89
-
-
Collins, P.1
Faradji, A.2
Morfini, M.3
Enriquez, M.M.4
Schwartz, L.5
-
21
-
-
0035106558
-
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia
-
van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
-
(2001)
Br J Haematol
, vol.112
, pp. 561-565
-
-
van den Berg, H.M.1
Fischer, K.2
Mauser-Bunschoten, E.P.3
-
22
-
-
0001776145
-
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis
-
Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
-
(1998)
Haemophilia
, vol.4
, pp. 83-88
-
-
Carlsson, M.1
Bjorkman, S.2
Berntorp, E.3
-
23
-
-
0030940593
-
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
-
Carlsson M, Berntorp E., Bjorkman S., Lethergen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
-
(1997)
Haemophilia
, vol.3
, pp. 96-101
-
-
Carlsson, M.1
Berntorp, E.2
Bjorkman, S.3
Lethergen, S.4
Ljung, R.5
-
24
-
-
0035543814
-
Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome
-
Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 444-50.
-
(2001)
Haemophilia
, vol.7
, pp. 444-450
-
-
Fischer, K.1
van der Bom, J.G.2
Prejs, R.3
-
25
-
-
11044225204
-
The impact of information technology on haemophilia care
-
Baker RI, Laurenson L, Winter M, Pritchard AM. The impact of information technology on haemophilia care. Haemophilia 2004; 10(Suppl. 4): 41-6.
-
(2004)
Haemophilia
, vol.10
, Issue.SUPPL. 4
, pp. 41-46
-
-
Baker, R.I.1
Laurenson, L.2
Winter, M.3
Pritchard, A.M.4
-
26
-
-
0038441404
-
Pilot study of an Internet-based electronic patient treatment record and communication system for haemophilia, Advoy.com
-
Collins PW, Bolton-Maggs P, Stephenson D, Jenkins B, Loran C, Winter M. Pilot study of an Internet-based electronic patient treatment record and communication system for haemophilia, Advoy.com. Haemophilia 2003; 9: 285-91.
-
(2003)
Haemophilia
, vol.9
, pp. 285-291
-
-
Collins, P.W.1
Bolton-Maggs, P.2
Stephenson, D.3
Jenkins, B.4
Loran, C.5
Winter, M.6
|